Genetic basis of Fanconi anemia

Current Opinion in Hematology

Volumn 10, Issue 1, 2003, Pages 68-76

  Bagby Jr , Grover C ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; RAD51 PROTEIN;

ACUTE NONLYMPHOCYTIC LEUKEMIA; APOPTOSIS; AUTOSOMAL RECESSIVE DISORDER; BONE MARROW DEPRESSION; DEVELOPMENTAL DISORDER; FANCONI ANEMIA; GENE MUTATION; GERM CELL; HUMAN; MYELODYSPLASIA; ONCOGENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; REVIEW; SOMATIC CELL;

FANCONI ANEMIA; GENETIC HETEROGENEITY; HUMANS; PROTEINS; SIGNAL TRANSDUCTION;

EID: 0037214260     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200301000-00011     Document Type: Review

References (96)

1. Fanconi G: Familiare infantile perniziosaartige anaemia (pernizioses blutbild und konstitution). Jahrb Kinderhilkd 1927, 117:257-280.
2. Joenje H, Patel KJ: The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet 2001, 2:446-459.
3. Alter BP, Caruso JP, Drachtman RA, et al.: Fanconi anemia: Myelodysplasia as a predictor of outcome. Cancer Genet Cytogenet 2000, 117:125-131.
4. Auerbach AD, Allen RG: Leukemia and preleukemia in Fanconi anemia patients: A review of the literature and report of the International Fanconi Anemia Registry. Cancer Genet Cytogenet 1991, 51:1-12.
5. Alter BP: Fanconi's anemia and malignancies. Am J Hematol 1996, 53:99-110.
6. Sasaki MS, Tonomura A: A high susceptibility of Fanconi's anemia to chromosome breakage by DNA cross-linking agents. Cancer Res 1973, 33:1829-1836.
7. Auerbach AD, Adler B, Chaganti RS: Prenatal and postnatal diagnosis and carrier detection of Fanconi anemia by a cytogenetic method. Pediatrics 1981, 67:128-135.
8. Cervenka J, Hirsch BA: Cytogenetic differentiation of Fanconi anemia, "idiopathic" aplastic anemia, and Fanconi anemia heterozygotes. Am J Med Genet 1983, 15:211-223.
9. Fagerlie S, Lensch MW, Pang Q, et al.: The Fanconi anemia group C gene product: Signaling functions in hematopoietic cells. Exp Hematol 2001, 29:1371-1381. This review article focuses on the function of FANCC, one of the Fanconi anemia proteins that is found largely in the cytoplasm. It reviews the experimental evidence from a variety of laboratories that supports the notion that FANCC functions as an antiapoptotic control point in multiple hematopoietic signaling pathways
10. Joenje H, Levitus M, Waisfisz Q, et al.: Complementation analysis in Fanconi anemia: Assignment of the reference FA-H patient to group A. Am J Hum Genet 2000, 67:759-762.
11. Morgan NV, Tipping AJ, Joenje H, et al.: High frequency of large intragenic deletions in the Fanconi anemia group A gene. Am J Hum Genet 1999, 65:1330-1341.
12. Howlett NG, Taniguchi T, Olson S, et al.: Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002, 297:606-609. Taking a cue from their own seminal findings that posttranslationally modified FANCD2 colocalizes with BRCA1 in cells exposed to genotoxic stress spurred on by the findings of Godthelp et al. [30• that localization of Rad51 to nuclear damage foci did not occur in FA-D1 mutant cells, this group has clearly shown that c-terminal truncated BRCA2 alleles missing the c-terminal Rad51 binding domain account for Fanconi anemia of the D1 type. Howlett et al. have successfully tied together the FA and BRCA pathways in an intriguing loop that must be clarified functionally, because the relation between these protein families may have relevance to maintenance of genomic integrity, carcinogenesis, leukemogenesis, and cell survival
13. Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L, et al.: Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. Nat Genet 1996, 14:320-323.
14. Strathdee CA, Gavish H, Shannon WR, et al.: Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature 1992, 356:763-767.
15. de Winter JP, Waisfisz Q, Rooimans MA, et al.: The Fanconi anaemia group G gene FANCG is identical with XRCC9. Nat Genet 1998, 20:281-283.
16. de Winter JP, Rooimans MA, van Der WL, et al.: The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nat Genet 2000, 24:15-16.
17. de Winter JP, Leveille F, van Berkel CG, et al.: Isolation of a cDNA representing the Fanconi anemia complementation group E gene. Am J Hum Genet 2000, 67:1306-1308.
18. Timmers C, Taniguchi T, Hejna J, et al.: Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell 2001, 7:241-248.
19. Garcia-Higuera I, Taniguchi T, Ganesan S, et al.: Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001, 7:249-262.
20. Christianson TA, Bagby GC: FANCA protein binds FANCG proteins in an intracellular complex [letter]. Blood 2000, 95:725-726.
21. de Winter JP, van Der WL, De Groot J, et al.: The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG. Hum Mol Genet 2000, 9:2665-2674.
22. Garcia-Higuera I, Kuang Y, Naf D, et al.: Fanconi anemia proteins FANCA, FANCC, and FANCG/XRCC9 interact in a functional nuclear complex. Mol Cell Biol 1999, 19:4866-4873.
23. Garcia-Higuera I, Kuang Y, Denham J, et al.: The Fanconi anemia proteins FANCA and FANCG stabilize each other and promote the nuclear accumulation of the Fanconi anemia complex. Blood 2000, 96:3224-3230.
24. Kruyt FAE, Abou-Zahr F, Mok H, et al.: Resistance to mitomycin C requires direct interaction between the Fanconi anemia proteins FANCA and FANCG in the nucleus through an arginine-rich domain. J Biol Chem 1999, 274:34212-34218.
25. Kupfer GM, Näf D, Suliman A, et al.: The Fanconi anaemia proteins, FAA and FAC, interact to form a nuclear complex. Nat Genet 1997, 17:487-490.
26. Waisfisz Q, de Winter JP, Kruyt FA, et al.: A physical complex of the Fanconi anemia proteins FANCG/XRCC9 and FANCA. Proc Natl Acad Sci U S A 1999, 96:10320-10325.
27. Medhurst AL, Huber PA, Waisfisz Q, et al.: Direct interactions of the five known Fanconi anaemia proteins suggest a common functional pathway. Hum Mol Genet 2001, 10:423-429.
28. Hoatlin ME, Christianson TA, Keeble WW, et al.: The Fanconi anemia group C gene product is located in both the nucleus and cytoplasm of human cells. Blood 1998, 91:1418-1425.
29. Naf D, Kupfer GM, Suliman A, et al.: Functional activity of the Fanconi anemia protein FAA requires FAC binding and nuclear localization. Mol Cell Biol 1998, 18:5952-5960.
30. Godthelp BC, Artwert F, Joenje H, et al.: Impaired DNA damage-induced nuclear Rad51 foci formation uniquely characterizes Fanconi anemia group D1. Oncogene 2002, 21:5002-5005. By exposing cells from all the known Fanconi anemia complementation groups to ionizing radiation and mitomycin C, these investigators discovered that only in FA-D1 cells did Rad51 fail to localize to nuclear damage foci. They concluded that FANCD1 was likely involved in repair of double-strand breaks by homologous recombination, given the known function of Rad51. These findings also catalyzed the search for a potential role of BRCA2 in FA-D1 cells [12•]
31. Xia F, Taghian DG, DeFrank JS, et al.: Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc Natl Acad Sci U S A 2001, 98:8644-8649. This report demonstrated that of the two major mechanisms available to cells for double-strand break repair, BRCA2 deficiency impairs homologous recombination (a mechanism that required Rad51!) but has no impact on nonhomologous end joining, a process that is more error-prone than homologous recombination
32. Davies AA, Masson J, McIlwraith MJ, et al.: Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 2001, 7:273-282.
33. Moynahan ME, Pierce AJ, Jasin M: BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001, 7:263-272.
34. Gowen LC, Avrutskaya AV, Latour AM, et al.: BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998, 281:1009-1012.
35. Husain A, He GS, Venkatraman ES, et al.: BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998, 58:1120-1123.
36. Le Page F, Randrianarison V, Marot D, et al.: BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. Cancer Res 2000, 60:5548-5552.
37. Aprelikova O, Pace AJ, Fang B, et al.: BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells. J Biol Chem 2001, 276:25647-25650.
38. Yarden RI, Brody LC: BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci U S A 1999, 96:4983-4988.
39. Zhang HB, Somasundaram K, Peng Y, et al.: BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 1998, 16:1713-1721.
40. Zheng L, Li S, Boyer TG, et al.: Lessons learned from BRCA1 and BRCA2. Oncogene 2000, 19:6159-6175.
41. Siddique H, Zou JP, Rao VN, et al.: The BRCA2 is a histone acetyltransferase. Oncogene 1998, 16:2283-2285.
42. Gao B, Shen XN, Kunos G, et al.: Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett 2001, 488:179-184.
43. Kubista M, Rosner M, Kubista E, et al.: Brca1 regulates in vitro differentiation of mammary epithelial cells. Oncogene 2002, 21:4747-4756.
44. Nadler JJ, Braun RE: Fanconi anemia complementation group C is required for proliferation of murine primordial germ cells. Genesis 2000, 27:117-123.
45. Koomen M, Cheng NO, van de Vrugt HJ, et al.: Reduced fertility and hypersensitivity to mitomycin C characterize Fancg/Xrcc9 null mice. Hum Mol Genet 2002, 11:273-281.
46. Cheng NC, van de Vrugt HJ, Van der Valk MA, et al.: Mice with a targeted disruption of the Fanconi anemia homolog Fanca. Hum Mol Genet 2000, 9:1805-1811.
47. + cells of patients with aplastic anaemia. Br J Haematol 1995, 91:245-252.
48. Cumming RC, Liu JM, Youssoufian H, et al.: Suppression of apoptosis in hematopoietic factor-dependent progenitor cell lines by expression of the FAC gene. Blood 1996, 88:4558-4567.
49. Cumming RC, Lightfoot J, Beard K, et al.: Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1. Nat Med 2001, 7:814-820.
50. Fagerlie SR, Diaz J, Christianson TA, et al.: Functional correction of FA-C cells with FANCC suppresses the expression of interferon gamma-inducible genes. Blood 2001, 97:3017-3024.
51. Haneline LS, Broxmeyer HE, Cooper S, et al.: Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from FAC -/- mice. Blood 1998, 91:4092-4098.
52. Koh PS, Hughes GC, Faulkner GR, et al.: The Fanconi anemia group C gene product modulates apoptotic responses to tumor necrosis factor-alpha and Fas ligand but does not suppress expression of receptors of the tumor necrosis factor receptor superfamily. Exp Hematol 1999, 27:1-8.
53. Li Y, Youssoufian H: MxA overexpression reveals a common genetic link in four Fanconi anemia complementation groups. J Clin Invest 1997, 100:2873-2880.
54. Pang Q, Keeble W, Christianson TA, et al.: FANCC interacts with hsp70 to protect hematopoietic cells from IFN-gamma/TNF-alpha-mediated cytotoxicity. EMBO J 2001, 20:4478-4489. Pang et al. [55] had already shown that a dominant-negative mutant of the double-stranded PKR was capable of completely reducing the characteristic hypersensitivity of FA-C cells to extracellular apoptotic cues. Taking cues from the research of Michael Katze [86,87], in this follow-up work, the group demonstrates that it is the capacity of FANCC to bind to hsp70 that is required to modulate the activity of PKR, and that suppression of hsp70 expression creates precisely the type of cytokine hypersensitivity seen in FANCC cells
55. Pang Q, Keeble W, Diaz J, et al.: Role of double-stranded RNA-dependent protein kinase in mediating hypersensitivity of Fanconi anemia complementation group C cells to interferon gamma, tumor necrosis factor-alpha, and double-stranded RNA. Blood 2001, 97:1644-1652.
56. Rathbun RK, Faulkner GR, Ostroski MH, et al.: Inactivation of the Fanconi anemia group C (FAC) gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells. Blood 1997, 90:974-985.
57. Wang J, Otsuki T, Youssoufian H, et al.: Overexpression of the Fanconi anemia group C gene (FAC) protects hematopoietic progenitors from death induced by Fas-mediated apoptosis. Cancer Res 1998, 58:3538-3541.
58. Otsuki T, Nagakura S, Wang J, et al.: Tumor necrosis factor-alpha and CD95 ligation suppress erythropoiesis in Fanconi anemia C gene knockout mice. J Cell Physiol 1999, 179:79-86.
59. Pang Q, Fagerlie S, Christianson TA, et al.: The Fanconi anemia protein FANCC binds to and facilitates the activation of STAT1 by gamma interferon and hematopoietic growth factors. Mol Cell Biol 2000, 20:4724-4735.
60. Rathbun RK, Christianson TA, Faulkner GR, et al.: Interferon-gamma-induced apoptotic responses of Fanconi anemia group C hematopoietic progenitor cells involve caspase 8-dependent activation of caspase 3 family members. Blood 2000, 96:4204-4211.
61. Marmorstein LY, Ouchi T, Aaronson SA: The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci U S A 1998, 95:13869-13874.
62. Stewart G, Elledge SJ: The two faces of BRCA2, a FANCtastic discovery. Mol Cell 2002, 10:2-4.
63. Kruyt FA, Hoshino T, Liu JM, et al.: Abnormal microsomal detoxification implicated in Fanconi anemia group C by interaction of the FAC protein with NADPH cytochrome P450 reductase. Blood 1998, 92:3050-3056.
64. Hoatlin ME, Zhi Y, Ball H, et al.: A novel BTB/POZ transcriptional repressor protein interacts with the Fanconi anemia group C protein and PLZF. Blood 1999, 94:3737-3747.
65. Dai MS, Chevallier N, Stone S, et al.: The effects of the Fanconi anemia zinc finger (FAZF) on cell cycle, apoptosis and proliferation are differentiation stage-specific. J Biol Chem 2002, 277:26327-26334.
66. Hoshino T, Wang JX, Devetten MP, et al.: Molecular chaperone GRP94 binds to the Fanconi anemia group C protein and regulates its intracellular expression. Blood 1998, 91:4379-4386.
67. Reddy RK, Lu J, Lee AS: The endoplasmic reticulum chaperone glycoprotein GRP94 with Ca(2+)-binding and antiapoptotic properties is a novel proteolytic target of calpain during etoposide-induced apoptosis. J Biol Chem 1999, 274:28476-28483.
68. Kupfer GM, Yamashita T, Naf D, et al.: The Fanconi anemia polypeptide, FAC, binds to the cyclin-dependent kinase, cdc2. Blood 1997, 90:1047-1054.
69. Otsuki T, Furukawa Y, Ikeda K, et al.: Fanconi anemia protein, FANCA, associates with BRG1, a component of the human SWI/SNF complex. Hum Mol Genet 2001, 10:2651-2660.
70. Beere HM: Stressed to death: Regulation of apoptotic signaling pathways by the heat shock proteins. Sci STKE 2001, 2001:RE1.
71. Jaattela M, Wissing D, Kokholm K, et al.: Hsp70 exerts its anti-apoptotic function downstream of caspase-3-1ike proteases. EMBO J 1998, 17:6124-6134.
72. Beere HM, Wolf BB, Cain K, et al.: Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2000, 2:469-475.
73. Williams BR: PKR; a sentinel kinase for cellular stress. Oncogene 1999, 18:6112-6120.
74. Gil J, Alcami J, Esteban M: Induction of apoptosis by double-stranded-RNA-dependent protein kinase (PKR) involves the alpha subunit of eukaryotic translation initiation factor 2 and NF-kappaB. Mol Cell Biol 1999, 19:4653-4663.
75. Pagano G: Mitomycin C and diepoxybutane action mechanisms and FANCC protein functions: Further insights into the role for oxidative stress in Fanconi's anaemia phenotype. Carcinogenesis 2000, 21:1067-1068.
76. Clarke AA, Philpott NJ, Gordon-Smith EC, et al.: The sensitivity of Fanconi anaemia group C cells to apoptosis induced by mitomycin C is due to oxygen radical generation, not DNA crosslinking. Br J Haematol 1997, 96:240-247.
77. Pang Q, Christianson TA, Keeble W, et al.: The Fanconi anemia complementation group C gene product: Structural evidence of multifunctionality. Blood 2001, 98:1392-1401. In the author's own scientific life, nothing had been more hotly contested than the arguments on localization and function of the Fanconi anemia proteins. Fortunately, much of the work on the nuclear complex pathway has solidified that the mitomycin C resistance pathway is both linear and nuclear; this pathway, as it is perturbed in all somatic cells, does not account for the unique involvement of hematopoiesis in the Fanconi anemia phenotype. Fortunately, it is now equally clear that some Fanconi anemia proteins have more than one function. The focus of the author's group has been on defining the hematopoietic function of Fanconi anemia proteins. This article describes the creation of site-directed mutations in a conserved domain of FANCC that are capable of fully complementing FA-C cells in mitomycin C assays but that do not complement in signaling assays specific for hematopoietic cells. This advance not only demonstrates the multifunctionality of FANCC but also raises the possibility that mutations of this kind might occur in nature and, if so, that some patients with bone marrow failure resulting from Fanconi anemia gene mutations might have normal mitomycin C tests
78. Yamashita T, Wu N, Kupfer G, et al.: Clinical variability of Fanconi anemia (type C) results from expression of an amino terminal truncated Fanconi anemia complementation group C polypeptide with partial activity. Blood 1996, 87:4424-4432.
79. Pang Q, Christianson TA, Keeble W, et al.: The anti-apoptotic function of Hsp70 in the PKR-mediated death signaling pathway requires the Fanconia anemia protein, FANCC. J Biol Chem 2003, in press.
80. Gregory JJ Jr, Wagner JE, Verlander PC, et al.: Somatic mosaicism in Fanconi anemia: Evidence of genotypic reversion in lymphohematopoietic stem cells. Proc Natl Acad Sci U S A 2001, 98:2532-2537.
81. Lensch MW, Rathbun RK, Olson SB, et al.: Selective pressure as an essential force in molecular evolution of myeloid leukemic clones: A view from the window of Fanconi anemia. Leukemia 1999, 13:1784-1789.
82. Lo Ten Foe JR, Kwee ML, Rooimans MA, et al.: Somatic mosaicism in Fanconi anemia: Molecular basis and clinical significance. Eur J Hum Genet 1997, 5:137-148.
83. Waisfisz Q, Morgan NV, Savino M, et al.: Spontaneous functional correction of homozygous Fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism. Nat Genet 1999, 22:379-383.
84. Giampietro PF, Auerbach AD, Elias ER, et al.: New recessive syndrome characterized by increased chromosomal breakage and several findings which overlap with Fanconi anemia. Am J Med Genet 1998, 78:70-75.
85. Carreau M, Gan OI, Liu L, et al.: Bone marrow failure in the Fanconi anemia group C mouse model after DNA damage. Blood 1998, 91:2737-2744.
86. Otsuki T, Wang J, Demuth I, et al.: Assessment of mitomycin C sensitivity in Fanconi anemia complementation group C gene (Fac) knock-out mouse cells. Int J Hematol 1998, 67:243-248.
87. Gale M Jr, Tan SL, Katze MG: Translational control of viral gene expression in eukaryotes. Microbiol Mol Biol Rev 2000, 64:239-280.
88. Tan SL, Katze MG: The emerging role of the interferon-induced PKR protein kinase as an apoptotic effector: A new face of death? J Interferon Cytokine Res 1999, 19:543-554.
89. Barber GN, Wambach M, Thompson S, et al.: Mutants of the RNA-dependent protein kinase (PKR) lacking double-stranded RNA binding domain I can act as transdominant inhibitors and induce malignant transformation. Mol Cell Biol 1995, 15:3138-3146.
90. Battaile KP, Bateman RL, Mortimer D, et al.: In vivo selection of wild-type hematopoietic stem cells in a murine model of Fanconi anemia. Blood 1999, 94:2151-2158.
91. Whysner J, Verna L, English JC, et al.: Analysis of studies related to tumorigenicity induced by hydroquinone. Regul Toxicol Pharmacol 1995, 21:158-176.
92. Brusamolino E, Papa G, Vlagussa P, et al.: Treatment related leukemia in Hodgkin's disease: A multi-institution study on 75 cases. Hematol Oncol 1987, 5:83-98.
93. Luna-Fineman S, Shannon KM, Lange BJ: Childhood monosomy 7: Epidemiology, biology, and mechanistic implications. Blood 1995, 85:1985-1999.
94. Rubin CM, Arthur DC, Woods WG, et al.: Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: Correlation between chromosomal abnormalities and prior therapy. Blood 1991, 78:2982-2988.
95. West RR, Stafford DA, White AD, et al.: Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure. Blood 2000, 95:2093-2097.
96. Whang-Peng J, Young RC, Lee EC, et al.: Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood 1988, 71:403-414.